XBP1 Governs Late Events in Plasma Cell Differentiation and Is not Required for Antigen-Specific Memory B Cell Development

Citation

Published Version
doi:10.1084/jem.20090738

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5978623

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development

Derrick J. Todd, Louise J. McHeyzer-Williams, Czeslawa Kowal, Ann-Hwee Lee, Bruce T. Volpe, Betty Diamond, Michael G. McHeyzer-Williams, and Laurie H. Glimcher

1Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115
2Division of Rheumatology, Allergy and Immunology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
3Department of Immunology and Microbial Sciences, Scripps Research Institute, La Jolla, CA 92037
4Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461
5Feinstein Institute for Medical Research, Autoimmune and Musculoskeletal Disease Center, Manhasset, NY 11030
6Department of Neurology and Neuroscience, Weill Medical College of Cornell University, Burke Cornell Medical Research Institute, White Plains, NY 10605

The unfolded protein response (UPR) is a stress response pathway that is driven by the increased load of unfolded proteins in the endoplasmic reticulum of highly secretory cells such as plasma cells (PCs). X box binding protein 1 (XBP1) is a transcription factor that mediates one branch of the UPR and is crucial for the development of antibody-secreting PCs. PCs represent only one class of terminally differentiated B cells, however, and little is known about the role for XBP1 in the other class: memory B cells. We have developed an XBP1<sup>fl/fl</sup> CD19<sup>Cre/Cre</sup> conditional knockout (XBP1<sup>CD19</sup>) mouse to build upon our current understanding of the function of XBP1 in PC differentiation as well as to explore the role of XBP1 in memory cell development. Using this model, we show that XBP1<sup>CD19</sup> mice are protected from disease in an autoimmune-mediated mouse lupus model. We also identify a novel developmental stage at which B cells express the traditional PC marker CD138 (synonymous with CD83) but have yet to undergo XBP1-dependent functional and morphological differentiation into antibody-secreting cells. Finally, we show that memory B cells develop normally in XBP1<sup>CD19</sup> mice, demonstrating that XBP1-mediated functions occur independently of any memory cell lineage commitment.

Proper protein folding is essential for normal immunoglobulin synthesis and secretion in antibody-secreting plasma cells (PCs). The mammalian unfolded protein response (UPR) is a signaling pathway that responds to ER stress that is induced by the accumulation of unfolded proteins within the ER lumen (Todd et al., 2008). Inositol-requiring transmembrane kinase/endonuclease 1 (IRE1) is an ER-localized transmembrane protein that senses unfolded proteins and serves to activate X-box binding protein 1 (XBP1), a member of the CREB/ATF basic leucine zipper family of transcription factors and a crucial mediator of one branch of the UPR (Yoshida et al., 2001; Calfon et al., 2002; Lee et al., 2002). IRE1 possesses endoribonuclease activity that excises a 26-nucleotide sequence from XBP1 messenger RNA (mRNA). This event, termed XBP1 splicing, shifts the reading frame to excise a premature stop codon, resulting in a full-length functional XBP1 protein product (Yoshida et al., 2001; Calfon et al., 2002; Lee et al., 2002). XBP1 then translocates to the nucleus where it induces target genes involved in protein synthesis and secretion (Shaffer et al., 2004; Lee et al., 2005).

XBP1 activation is crucial to the normal function and survival of highly secretory cells such as exocrine gland acinar cells and Paneth cells (Kaser et al., 2008). Using XBP1/RAG2<sup>−/−</sup> lymphoid chimeric mice, we have shown...
previously that XBP1 expression is required for normal PC
development and function as well (Reimold et al., 2001). Chimeric mice demonstrated markedly reduced serum Ig
levels and impaired Ig response to immunization. This defect
was the result of a failure of cells to up-regulate UPR-related
XBP1 target genes during terminal B cell differentiation
(Iwakoshi et al., 2003; Shaffer et al., 2004). The requirement
of XBP1 for PC differentiation raises the possibility that dis-
ruption of XBP1 activity may represent a potential therapeu-
tic target for the treatment of autoimmune diseases, such as
systemic lupus erythematosus (SLE), in which autoantibodies
may be directly pathogenic.

Little is known about the role of XBP1 in the develop-
ment and function of another important B cell population:
memory B cells. These B cells have been exposed to antigen,
undergo a germinal center (GC) reaction, and function to
differentiate rapidly into antibody-secreting B cells after
reexposure to cognate antigen (for review see McHeyzer–
Williams and McHeyzer-Williams, 2005). They do not express
CD138 (syndecan-1), a cell surface glycoprotein which has
traditionally been used a marker for Ig-secreting PCs
(Sanderson and Børset, 2002). Memory B cells also function to
replete the pool of long-lived antibody-secreting PCs (for
review see McHeyzer-Williams and McHeyzer-Williams, 2005),
which may represent a persistent source of autoantibodies
(Neubert et al., 2008).

The recent development of a XBP1<sup>flox</sup> conditional KO
(cKO) mouse (Hetz et al., 2008) has prompted us to explore
further the function of XBP1 in terminal B cell development.
CD19 expression is limited to B cells and occurs in pro–B
cells and throughout the remaining stages of B cell develop-
ment (Zhou et al., 1991; Hardy and Hayakawa, 2001). We
therefore bred the XBP1<sup>flox</sup> cKO mouse to a mouse express-
ing CRE recombinase under the control of CD19 promoter
to delete XBP1 selectively from B cells (Rickert et al., 1997).
In the current series of experiments, we use XBP1<sup>flox/flox</sup>
CD19<sup>Cre/−</sup> (XBP1<sup>CD19</sup>) cKO mice first to confirm the func-
tional PC defects in XBP1<sup>CD19</sup>/RAG2<sup>−/−</sup> lymphoid chimeric
mice (Reimold et al., 2001). In addition, we now report that
XBP1<sup>CD19</sup> mice were protected from mouse lupus. We also
show, unexpectedly, that the number of cells with the tradi-
tional B220<sup>+</sup> CD138<sup>+</sup> PC phenotype is normal in XBP1<sup>CD19</sup>
mice as compared with XBP1<sup>flox/flox</sup> CD19<sup>+/+</sup> (XBP1<sup>+/+</sup>)
controls. Finally, we report that XBP1<sup>CD19</sup> mice have normal
populations of memory B cells, demonstrating that this alter-
native differentiation pathway for B cells is not dependent on
the XBP1 branch of the UPR.

RESULTS AND DISCUSSION
Initial characterization of XBP1<sup>CD19</sup> cKO mice

To determine the efficiency of XBP1 deletion in the B cells
in XBP1<sup>CD19</sup> mice, splenocytes from these mice were isolated
and separated into B220<sup>+</sup> and B220<sup>−</sup> populations using mag-
netic beads coupled to an anti-B220 mAb. Southern blotting
demonstrated efficient and specific deletion of XBP1 in the
B220<sup>+</sup> (B cell) fraction (Fig. S1 A). There were no differences
in cell surface expression of IgM and IgD between XBP1<sup>CD19</sup>
and XBP1<sup>+/+</sup> splenocytes (Fig. S1 B). In accord with the
known function of XBP1 in PC development, basal Ig levels
were markedly reduced in XBP1<sup>CD19</sup> mice (Fig. S1 C). Fur-
thermore, these mice exhibited impaired Ig responses to the
T cell–dependent antigen nitrophenol (NP)–KLH upon pri-
mary or secondary stimulation (Fig. S2, A and B, respect-
ively). A similar defect was observed in mice immunized
with the T cell–dependent antigen NP-ficoll (Fig. S2 C).

XBP1 up-regulates the expression of UPR-related target
genesis that function collectively in protein synthesis and se-
cretion. XBP1 targets include the ER–associated degradation
protein EDEM, ER–localized chaperones like ER–localized
Dnabj9 (ERdj4), the ER translocon component Sec61α, and
proteins, such as protein disulfide isomerase (PDI), that aid
disulfide bond formation (Todd et al., 2008). Using B220<sup>+</sup>
splenocytes isolated from XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice, we
next measured the expression of XBP1 target genes in these
B cells after culture for 0–3 d in the presence or absence of
10 μg/ml LPS (Fig. S3 A). As expected, quantitative PCR
analysis demonstrated that, by day 3 of culture, there were
significant increases in the expression of the aforementioned
XBP1 target genes in XBP1<sup>+/+</sup> B cells. These same target
genesis were up-regulated to a lesser degree or not at all in
XBP1<sup>CD19</sup> B cells. In addition, XBP1<sup>CD19</sup> B cells did not
demonstrate an appropriate up-regulation of μS, which nor-
normally allows for newly synthesized IgM to be secreted.
Importantly, B cells from XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice showed
no difference in their modest increase in expression of Ig
heavy chain binding protein (BiP), another UPR related
gene which is not directly downstream of XBP1.

XBP1 deletion did not affect B cell proliferation or viability
in response to LPS treatment. Both were comparable be-
tween XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> B cells as measured by exclusion
of 7-amino-actinomycin D (7-AAD) and annexin V (Fig. S3 B)
or by exclusion of trypan blue (Fig. S3 C). In contrast, XBP1
deletion led to markedly reduced secretion of IgM by LPS-
stimulated XBP1<sup>CD19</sup> B cells (Fig. S3 D). Collectively, these
data demonstrate that XBP1 deletion leads to defects in the
UPR that impair normal synthesis and secretion of immuno-
oglobulin without affecting B cell viability or proliferative
properties. Importantly, these initial experiments in XBP1<sup>CD19</sup>
mice recapitulated the known roles of XBP1 in PC develop-
ment and function, as has been shown previously using XBP1/
RAG2<sup>−/−</sup> lymphoid chimeric mice (Reimold et al., 2001).

We next investigated the impact of XBP1 deficiency on
the broader network of transcriptional regulators that direct
PC differentiation (for review see Calame et al., 2003). The
transcription factors Bcl-6 (B cell lymphoma 6) and paired
box gene 5 (Pax5) repress B lymphocyte–induced maturation
protein 1 (Blimp1) and IFN regulatory factor 4 (IRF4), respec-
tively, and promote B cell proliferation and the GC reac-
tion. On the contrary, Blimp1 and IRF4 normally arrest cell
cycle progression and the GC reaction to promote and sus-
tain PC development (Calame et al., 2003). Furthermore,
Blimp1 and IRF4 permit the expression of XBP1 (Shaffer
When treated with bortezomib, these lupus-prone mice lacked autoantibodies, were devoid of mature PCs, and were protected from mouse lupus. Proteasome inhibitors suppress ER-associated degradation pathways such that misfolded proteins accumulate in cells, cause ER stress, and induce the UPR (Obeng et al., 2006). Chronic ER stress, however, causes cell cycle arrest and cellular apoptosis (Zinszner et al., 1998; Brewer and Diehl, 2000). Proteasome inhibitors like et al., 2004; Klein et al., 2006). For Blimp1, this regulatory event is accomplished by Blimp1-mediated repression of Pax5, which derepresses XBP1 to ensure an appropriate UPR in anticipation of Ig production and secretion (Shaffer et al., 2004). Despite the failure to differentiate into Ig-secreting PCs, LPS-stimulated XBP1CD19 B cells displayed a typical PC signature of these transcription factors: down-regulation of Pax5 and up-regulation of Blimp1 and IRF4 mRNAs. Interestingly, Blimp1 and IRF4 were substantially overexpressed in LPS-stimulated XBP1CD19 B cells compared with XBP1+/+ controls (Fig. S3 A). These data suggest that XBP1 deletion did not alter the genetic program of PC development. Furthermore, failure to up-regulate Ig secretion in the absence of XBP1 appears to promote the PC developmental program, supporting the hypothesis that a mechanism of feedback inhibition exists whereby XBP1 down-regulates Blimp1 and IRF4 expression in LPS-stimulated B cells (Hu et al., 2009).

Mice with XBP1-deficient B cells are protected from mouse lupus

BALB/c mice develop anti-double-stranded DNA (dsDNA) autoantibodies and immune complex deposits in glomeruli when immunized with a DNA mimotope, the decapptide DWEYSVWLSN on a polylysine backbone (MAP-DWEYS; Putterman and Diamond, 1998). Furthermore, when treated with LPS to disrupt the blood brain barrier, MAP-DWEYS-immunized mice develop lesions in the hippocampus of the brain, a process which is attributable to excitatory cell death induced by stimulatory autoantibodies bound to neuronal N-methyl-D-aspartic acid (NMDA) receptors (Kowal et al., 2004). Anti-NMDA receptor autoantibodies have also been identified in the cerebrospinal fluid of humans with SLE, and this mouse system has been used as a model of human central nervous system lupus (DeGiorgio et al., 2001; Kowal et al., 2006).

We next sought to use this mouse model of SLE to test whether XBP1CD19 mice were capable of developing autoantibodies and associated pathological findings of mouse lupus. XBP1CD19 and litter-matched XBP1+/+ mice were immunized with MAP-DWEYS three times over a 1-mo period, as described in Materials and methods. Serum anti-peptide and anti-dsDNA antibodies were readily detected in XBP1+/+ control mice but were only weakly present in XBP1CD19 mice (Fig. 1, A and B). These same mice were then treated with 3 mg/kg LPS and killed 4–7 d later for immunohistochemistry (IHC) analysis of kidney and brain (Fig. 1 C). IHC revealed abundant IgG in glomeruli of five out of five control mice and in the hippocampus of two out of five controls, but none was present in any of the XBP1CD19 mouse tissues. Thus, mice with B cells deficient in XBP1 were protected from autoantibody production and disease expression in this mouse model of SLE.

This observation is reminiscent of a recent compelling study in which two lupus-prone mouse strains (NZB/W F1 and MRL/lpr) were treated with bortezomib, a selective inhibitor of the 26S proteasome which is used therapeutically to treat human myeloma, a PC malignancy (Neubert et al., 2008). When treated with bortezomib, these lupus-prone mice lacked autoantibodies, were devoid of mature PCs, and were protected from mouse lupus. Proteasome inhibitors suppress ER-associated degradation pathways such that misfolded proteins accumulate in cells, cause ER stress, and induce the UPR (Obeng et al., 2006). Chronic ER stress, however, causes cell cycle arrest and cellular apoptosis (Zinszner et al., 1998; Brewer and Diehl, 2000). Proteasome inhibitors like et al., 2004; Klein et al., 2006). For Blimp1, this regulatory event is accomplished by Blimp1-mediated repression of Pax5, which derepresses XBP1 to ensure an appropriate UPR in anticipation of Ig production and secretion (Shaffer et al., 2004). Despite the failure to differentiate into Ig-secreting PCs, LPS-stimulated XBP1CD19 B cells displayed a typical PC signature of these transcription factors: down-regulation of Pax5 and up-regulation of Blimp1 and IRF4 mRNAs. Interestingly, Blimp1 and IRF4 were substantially overexpressed in LPS-stimulated XBP1CD19 B cells compared with XBP1+/+ controls (Fig. S3 A). These data suggest that XBP1 deletion did not alter the genetic program of PC development. Furthermore, failure to up-regulate Ig secretion in the absence of XBP1 appears to promote the PC developmental program, supporting the hypothesis that a mechanism of feedback inhibition exists whereby XBP1 down-regulates Blimp1 and IRF4 expression in LPS-stimulated B cells (Hu et al., 2009).
bortezomib are toxic to myeloma cells, in part through targeting the activity of IRE1 (Lee et al., 2003; Obeng et al., 2006). These findings raise the intriguing notion that inhibition of XBP1 or the UPR in general may represent a potential therapeutic target in the treatment of autoimmune-mediated diseases like SLE.

The developmental defect in XBP1-deficient PCs occurs after CD138 expression

XBP1<sup>CD19</sup> mice allow us to explore further the developmental stage at which PC differentiation arrests. Complicating this analysis, however, is the observation that PCs down-regulate many B cell surface markers such as B220, CD19, and CD20 (Hardy and Hayakawa, 2001). Traditionally, cell surface expression of CD138 by B cells has been viewed as a marker for antibody-secreting PCs (B220<sup>+</sup>CD138<sup>+</sup> cells; Sanderson and Borset, 2002). Accordingly, we immunized XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice with NP-KLH to measure the distribution of B220 and CD138 staining over time. Surprisingly, even though XBP1<sup>CD19</sup> mice had markedly impaired Ig responses to immunization (Fig. S2), both XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice had comparable numbers of B220<sup>CD138</sup> splenocytes (Fig. 2 A). In XBP1<sup>CD19</sup> mice, these cells lacked the expanded ER and perinuclear cuff of Golgi found in normal PCs (Fig. 2 B). This difference was quantifiable; B220<sup>CD138</sup> cells from XBP1<sup>CD19</sup> mice demonstrated less intensive staining by brefeldin A boron–dipyrromethane (BODIPY), which selectively binds to secretory ER and Golgi content (Fig. 2 C) (Hetz et al., 2008).

5 d after NP-KLH immunization, splenocytes from XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice were isolated and FACS sorted into B220<sup>CD138</sup> and B220<sup>−</sup>CD138<sup>−</sup> cell populations, from which RNA was purified for quantitative PCR analysis. In accord with what is known about PCs, B220<sup>CD138</sup> cells from XBP1<sup>−/−</sup> mice expressed much greater levels of the XBP1 target genes ERdj4, EDEM, PDI, and Sec61 as compared with B220<sup>CD138</sup> cells from the same mice (Fig. 3). There were also increased levels of BiP, µS, Blimp1, and IRF4 and reduced levels of Pax5. These differences were also observed, but to a much lesser degree, in the two sorted XBP1<sup>CD19</sup>B cell populations. When comparing B220<sup>CD138</sup> cells from XBP1<sup>CD19</sup> and XBP1<sup>+/+</sup> mice, XBP1 target genes and µS were reduced in expression in cKO cells, and levels of BiP and Pax5 were similar. Unlike what was observed in LPS-stimulated B cells, however, levels of Blimp1 and IRF4 were not elevated in cells from XBP1<sup>−/−</sup> mice. This supports the hypothesis that there are multiple pathways of B cell differentiation depending on the specific exogenous stimulus. Indeed, in vitro LPS-stimulated B cells behave differently than in vivo immunogen-stimulated B cells, and this is likely caused, in part, by the absence of T helper cell activity as well as by the different activation pathways involved (for review see McHeyzer-Williams and McHeyzer-Williams, 2005).

Collectively, our data show that XBP1<sup>CD19</sup> B cells can survive and differentiate to the developmental stage at which they express CD138, at which point they developmentally arrest. This occurs before achieving normal PC morphology and functional activity because of a failure to up-regulate XBP1-dependent UPR target genes. CD138 is a member of the syndecan family of heparin sulfate proteoglycans and is comprised of a transmembrane core protein covalently bonded to heparin sulfate moieties (Sanderson and Yang, 2008). CD138 also exists as part of the bone marrow stroma and in a soluble form that may be shed from cell membranes. Cell surface–bound CD138 impairs invasion of myeloma cells through collagen gels (Liebersbach and Sanderson, 1994), facilitates cell–cell aggregation (Stanley et al., 1995), and promotes myeloma adhesion to collagen in the extracellular matrix (Riley et al., 1993). These functions have been hypothesized to explain the organ selectivity of myeloma

![Figure 2](image-url)
cells, and CD138 is being investigated as a potential therapeutic target in myeloma (Sanderson and Yang, 2008).

The role of CD138 in normal PCs, however, is less well defined, although it may have similar bone marrow homing functions in PCs as in myeloma cells. CD138 is expressed on the cell surface of PCs and bone marrow–resident B cell precursors. It is not present on the surface of mature naive B cells in the bone marrow, circulation, or secondary lymphoid organs (Sanderson et al., 1989). CD138 expression has been closely correlated with Ig secretion (Lalor et al., 1992), and CD138+ plasmablasts have been previously described (Angelin-Duclos et al., 2000), but the existence of a non-Ig-secreting CD138+ cell population has not been formally demonstrated until now. The converse has been seen, however, in that Blimp1-deficient B cells do not express CD138 but can secrete small amounts of Ig (Shapiro-Shelef et al., 2003; Kallies et al., 2007). However, this represents an earlier (initial) developmental stage of PC differentiation in that these cells are unable to attain the large secretory capabilities or phenotype of mature PCs (Kallies et al., 2007). IRF4-deficient B cells also fail to express CD138 (Klein et al., 2006).

Our findings therefore indicate that in developing PCs, Blimp1 and IRF4 expression precedes CD138 expression, which is then followed by XBP1-directed UPR transcriptional events and large-scale immunoglobulin secretion. This differs from our previously published results in which CD138 was not detected on the surface of XBP1-deficient B cells 9 d after immunization with 2,4-dinitrophenyl (DNP)-albumin in XBP1/RAG2−/− lymphoid chimeric mice (Reimold et al., 2001). One limitation of the XBP1/RAG2−/− lymphoid chimeric model, however, is that it cannot ascribe this difference solely to an intrinsic deficiency of XBP1 in B cells. With the recent discovery that XBP1 is important for the normal development and function of dendritic cells (Iwakoshi et al., 2007), one could conjecture that XBP1 function in non–B cell populations might in part explain the reduced numbers of CD138+ cells in the chimeric mice. Thus, the XBP1CD19−/− cKO system provides some refinement in our understanding of the relationship between XBP1 and CD138 expression.

**Post-GC memory cells and preplasma memory cells are intact in mice with B cells that lack XBP1**

Memory B cells make up the second major population of terminally differentiated B cells (for review see McHeyzer-Williams and McHeyzer-Williams, 2005). They are long-lived antigen-specific cells that reside mainly in peripheral

---

**Figure 3.** XBP1+/+ and XBP1CD19−/− mice were immunized i.p. with a single 100-µg dose of NP-KLH in alum. At day 5 after immunization, splenocytes were isolated and sorted by FACS for B220+ CD138− (B220) and B220+ CD138+ (CD138) populations. Panels show relative expression of indicated mRNA versus actin as measured by RT-PCR of cDNA prepared from indicated cell populations. In all panels, each bar represents the mean ± SEM value of individual XBP1+/+ (open bar) and XBP1CD19−/− (solid bar) mice in three independent experiments.
tissues, including in the lung, gut, and peripheral lymphoid organs. When reexposed to cognate antigen, memory B cells proliferate, and a subset differentiates into antibody-secreting PCs. Memory B cell subpopulations can be distinguished phenotypically as post-GC B cells (B220⁺ CD138⁻) or preplasma memory B cells (B220⁻ CD79b⁺ CD138⁺; for review see McHeyzer-Williams and McHeyzer-Williams, 2005).

Little is known about the transcriptional programs that regulate B cell differentiation into memory cells, including whether there is any role for XBP1 or the UPR in this process. Neither Blimp1 nor IRF4 are required for the development of post-GC memory B cells (Shapiro-Shelef et al., 2003; Klein et al., 2006). Blimp1-deficient B cells, however, fail to differentiate into preplasma memory B cells (Shapiro-Shelef et al., 2003). Furthermore, IRF4-deficient post-GC B cells can expand upon reencounter with cognate antigen (a memory cell–driven response), but they fail to differentiate into PCs (Klein et al., 2006). Thus, neither of these transcription factors appears to be crucial for development of the memory B cell population de novo.

Figure 4. Memory B cells are present in normal numbers in XBP1<sup>CD19</sup> mice. (A, left) Representative expression of IgD and NP on [PI, CD4, CD8, F4/80, GR1]<sup>neg</sup> splenocytes of day-14 mice immunized with Ribi (adjuvant) only (left) or NP-KLH in Ribi (right). Shown are XBP1<sup>fl/fl</sup>CD19<sup>+/+</sup> (XBP1<sup>+</sup>) mice (top) and XBP1<sup>fl/fl</sup>CD19<sup>cre/+</sup> (XBP1<sup>CD19</sup>) littermates (bottom). The inset represents the percentage of cells within profile (mean ± SEM; n = 3). (A, right) Total number of IgD<sup>lo</sup> NP-specific B cells from day 0 (naive BALB/c), adjacent only (day 14 Ribi only), day 5, and day 14 NP-KLH in Ribi immunized XBP1<sup>+</sup> mice (white columns) and XBP1<sup>CD19</sup> (black columns) mice (mean ± SEM; n = 3). (B, left) Representative expression of B220 and CD138 at the surface of IgD<sup>lo</sup> NP-specific B cells at days 5 (left) and 14 (right) from XBP1<sup>+</sup> mice (top) and XBP1<sup>CD19</sup> littermates (bottom). The inset represents the percentage of cells within profile (mean ± SEM; n = 3). (B, right) Total number of NP-specific B cells compartment B220⁺ CD79b⁺ CD138⁺ at day 5 (top) or day 14 (bottom) immunized XBP1<sup>+</sup> (white columns) and XBP1<sup>CD19</sup> (black columns) mice (mean ± SEM; n = 3; unpaired Student’s t test; P > 0.05 for all data points). (C) [PI, CD4, CD8, F4/80, GR1]<sup>neg</sup> IgD<sup>lo</sup> NP-specific B cells from day-5 and day-14 immunized mice were sorted directly ex vivo into NP-specific Ig (IgM or IgG) revealing ELISPOT assays. Positives were scored manually under a dissection microscope. Each assay was done in triplicate from three separate animals (mean ± SEM; n = 3; unpaired Student’s t test; *, P ≤ 0.05).
We have already demonstrated that secondary Ig responses are markedly blunted in XBP1^{CD19} mice (Fig. S2). Using a well established protocol to study memory B cells (Shapiro-Shelef et al., 2003), we next sought to answer whether the defect in secondary memory responses in XBP1^{CD19} mice is solely attributable to impaired antibody secretion by PCs or whether there may also be independent deficiencies in memory B cell populations themselves. Mice were immunized with 400 µg NP-KLH in Ribi adjuvant and splenocytes were isolated at day 5 or 14. Cells were stained with antibodies specific for CD4, CD8, F4/80 (a macrophage marker), GR1 (a granulocyte and monocyte marker), B220 (CD45R), CD138, IgD, GL7, CD38, and Igλ light chain. In addition, cells were stained with propidium iodide (PI) to determine viability and allophycocyanin (APC)-conjugated NP to identify antigen-specific B cells. Viable post-GC NP-specific B cells were identified as those cells that excluded PI, were [CD4, CD8, F4/80, GR1]^{neg}, and demonstrated a NP^{+}IgD^{lo} phenotype. The expansion of these cells after immunization was comparable between XBP1^{CD19} and XBP1^{+/+} mice (Fig. 4 A).

These NP-specific B cells were further assayed for expression of B220 and CD138 to identify B220^{hi} CD138^{−} post-GC memory cells, B220^{lo} CD79b^{−} CD138^{−} preplasma memory cells, and B220^{lo} CD138^{+} cells with a PC phenotype (Fig. 4 B). By day 5 after immunization, there were no differences in the relative or absolute numbers of the subpopulations between XBP1^{CD19} and XBP1^{+/+} mice. At day 14, there were some differences in the relative numbers of these cells, but the absolute numbers were not significantly different because the number of splenocytes and absolute number of NP-specific cells were up to twofold greater in XBP1^{CD19} mice. There were no differences in the total number of antigen-specific GC versus post-GC events at day 14 as measured by CD138^{neg} GL7^{hi} CD38^{lo} GC B cells versus CD138^{neg} GL7^{lo} CD38^{+} post-GC B cells (Fig. S4 A). There were also no differences between XBP1^{CD19} and XBP1^{+/+} mice when assayed for the repertoire of light chain expression by antigen-specific B cells (Fig. S4 B). ELISPOT was used to measure the ability of FACS-purified B220^{lo} CD138^{+} cells to secrete IgM and IgG. At days 5 and 14, the number of NP-specific IgG-secreting B cells was significantly reduced in XBP1^{CD19} mice as compared with controls (Fig. 4 C). Similar results were obtained for NP-specific IgM-secreting cells at day 5 but not at day 14. These assays reinforce the notion that XBP1^{CD19} B cells are able to differentiate into B220^{lo} CD138^{+} cells but lack the normal capacity for Ig secretion.

Thus, XBP1^{CD19} B cells are capable of differentiating normally into post-GC or preplasma memory B cell populations. These observations again place XBP1-mediated events downstream of Blimp1, which is crucial for the development of preplasma memory B cell (Shapiro-Shelef et al., 2003). These data also show for the first time that the XBP1-driven branch of the UPR is unnecessary for the development of memory B cells themselves. Thus, the defects in Ig production during secondary antigen challenge in XBP1^{CD19} mice are solely the result of a failure of formation of antibody-secreting PCs and not of B cell memory itself.

Summary
Collectively, this analysis of B cells from XBP1^{CD19} cKO mice expands our understanding of the crucial role of XBP1 in terminal B cell development as it pertains to PC development, autoantibody-mediated autoimmune disease, and memory cell development. Deletion of XBP1 leads to failed up-regulation of the UPR in developing PCs with subsequent deficiencies in antibody responses to antigen. Interestingly, the experiments presented here identify and characterize a previously unrecognized population of antibody hyposecreting B220^{lo} CD138^{+} B cells in XBP1^{CD19} mice, demonstrating that XBP1-mediated UPR events occur after the developmental stage at which CD138 is expressed. Importantly, we establish that memory B cell populations are unaffected by XBP1 deficiency such that XBP1-related activity can be situated independent of the memory B cell lineage commitment. Finally, XBP1^{CD19} mice are protected from autoantibody-mediated mouse lupus. This has therapeutic implications from a clinical perspective in that inhibition of XBP1 or the UPR in general potentially represents a therapeutic target in the treatment of SLE.

MATERIALS AND METHODS
Mice and immunization. The creation of XBP1^{lox/lox} mice harboring loxP sites in the first and second intron of the XBP1 gene has been described previously (Hetz et al., 2008; Kaser et al., 2008; Lee et al., 2008). These mice were backcrossed 10 generations with BALB/c mice, which was the background strain for all experiments described in these studies. XBP1^{lox/lox} mice were bred to CD19^{+/−} BALB/c mice that express cre recombinase under the control of the CD19 promoter (The Jackson Laboratory; Rickett et al., 1997). Two generations of breeding yielded XBP1^{CD19} cKO mice and XBP1^{+/−} control mice. All mice were born in Mendelian ratios and developed normally. Wild-type BALB/c mice were purchased from Taconic. Experimental protocols were approved by the Standing Committee on Animals at the Harvard Medical School and were designed with institutional and National Institutes of Health guidelines for the humane use of animals.

To measure serum antibody responses to immunization, 6–8-wk-old XBP1^{CD19} and XBP1^{+/−} mice were injected i.p. with 100 µg NP-KLH (Bioresearch Technologies) emulsified in alum (Thermo Fisher Scientific) or 25 µg NP-ficol (Bioresearch Technologies). Blood was collected from mice via retroorbital bleed at the time of immunization and weekly for 2 wk. To measure secondary serum antibody responses, some mice that had received NP-KLH were reimmunized with 100 µg NP-KLH in alum 8 wk after primary immunization, and additional blood samples were obtained at the time of reimmunization and weekly for 2 wk. For NP-specific B cell studies, 8–14-wk-old mice were immunized subcutaneously with 400 µg NP-KLH in Ribi adjuvant (laboratory formulation based on Baldridge and Crane [1999]).

B cell isolation and culture. Single cell suspensions of splenocytes were prepared from 6–8-wk-old mice, and erythrocytes were removed by osmotic lysis with NH4Cl buffer (Sigma-Aldrich) as previously described (Iwakoshi et al., 2003). Splenic B cells were purified using B220^{+} magnetic bead selection (Miltenyi Biotech) and confirmed to have >90% purity by flow cytometry for cell surface CD19 expression. For some B cell preparations, Southern blotting was used to determine efficacy of XBP1 deletion in B220^{hi} lymphocytes. The remaining B220^{lo} splenocytes from XBP1^{CD19} and XBP1^{+/−} mice were cultured at 10^{6} cells/ml for 0–3 d in the presence or absence of 10 µg/ml LPS (Sigma-Aldrich) in complete media containing...
RPMI 1640 supplemented with 10% FBS (Hyclone Laboratories), 2 mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 100 mM Hepes, nonessential amino acids, 1 mM sodium pyruvate, and 50 µM β-mercaptoethanol. Cells were harvested on days 0–3 of culture for RNA extraction and quantitative PCR analysis. In addition, on day 3 of culture, supernatants were tested by enzyme-linked immunosorbent assay ELISA to quantify IgM production, cells were harvested for viability assay by annexin V and 7-AAD staining, and cell counts by exclusion of trypan blue.

**Flow cytometry and cell sorting.** Spleenocytes were prepared as described in the previous section. Non–NP-specific flow cytometry and FACS were performed using antibodies specific for mouse IgM, IgD, B220, CD19, or CD138 (BD) as previously described (Iwakoshi et al., 2007). To measure cell viability, cells were stained with PE-conjugated annexin V and 7-AAD according to manufacturer instructions (BD). Viable cells exclude both stains. To measure the cellular content of ER and Golgi organelles, cells were stained with Brefeldin A–BODIPY (Invitrogen) at 0.2 µg/ml at 37°C for 40 min before flow cytometric analysis as previously described (Hetzel et al., 2008). Cytospin samples of FACS-sorted B220+ CD138+ cells were prepared from XBP1+/- and XBP1+/- mice and stained with modified Wright-Giemsa stain according to the manufacturer’s instructions (Sigma-Aldrich).

For NP-specific B cell studies, spleens were harvested at 5 or 14 days after immunization and single cell suspensions were prepared as previously described (McHeyzer-Williams et al., 2000). Cells suspensions were labeled for flow cytometry at 2 × 10⁶ cells/ml on ice for 45 min with the following fluorophore-labeled mAbs or Ag: FITC–11.26 (anti-IgD; McHeyzer-Williams laboratory), FITC–GL7 (BD), PE–281.2 (anti-CD138/syndecan-1; BD), PE–90 (anti-CD38; BD), Cy5–H129.19 (anti-CD4; BD), Cy5/P–53–6.7 (anti-CD8; Biolllegend), Cy5/P–F4/80 (eBiosciences), Cy5/P–RB6–8C5 (anti-Ly6G/GR1), Cy5/P–6B2 (anti-CD45R/B220), APC–NP (4-hydroxy-5-undo–3-nitrophenyl; McHeyzer-Williams laboratory), and biotin–HM79b (anti-CD79b/IgM; McHeyzer-Williams laboratory). Streptavidin–Cy7/APC (BD) was used as a second-step Reveling reagent. Cells were washed and re-suspended in 2 µg/ml PI for dead cell exclusion in PBS with 5% FCS for analysis. Samples were analyzed using a FACS Vantage SE (BD) and data analyzed using FlowJo software (Tree Star, Inc.). Profiles are presented as 5% probability contours with outliers.

**ELISA and ELISPOT assays.** ELISA was used to quantify IgM levels in cell culture supernatants and levels of IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA in the serum of XBP1+/- and XBP1+/- mice as previously described (Reimold et al., 2001). To measure the relative amounts of NP-specific serum antibodies in mice immunized with NP-KLH or NP-ficoll, plates were coated with 25 µg/ml NP/BSA (Biosearch Technology) overnight at 4°C. To standardize and quantify relative amounts of NP-specific IgG responses, all experimental samples were compared with a standardized dilution of pooled serum obtained from XBP1+/- mice immunized with NP-KLH or NP-ficoll and bled on day 14. NP-specific ELISA was otherwise performed as previously described (Reimold et al., 2001). Serum anti-peptide and anti-dsDNA antibodies were tested by ELISA as previously described (Kowal et al., 2004).

ELISPOT for detection of NP-specific Ig was performed as described previously (McHeyzer-Williams et al., 1993; McHeyzer-Williams et al., 2000), 96-well multiscreen membrane filtration plates (Millipore) were coated with 25 µg/ml NP/BSA (Biosearch Technology) overnight at 4°C. To standardize and quantify relative amounts of NP-specific IgG responses, all experimental samples were compared with a standardized dilution of pooled serum obtained from XBP1+/- mice immunized with NP-KLH or NP-ficoll and bled on day 14. NP-specific ELISA was otherwise performed as previously described (Reimold et al., 2001). Serum anti-peptide and anti-dsDNA antibodies were tested by ELISA as previously described (Kowal et al., 2004).

**Quantitative PCR.** Total RNA was isolated from cells using TRizol reagent (Invitrogen), and complementary DNA (cDNA) was synthesized from RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative real-time PCR reactions using SYBR green fluorescence reagent were run in an MX3005P system (Agilent Technologies) and analyzed as previously described (Iwakoshi et al., 2007). Primer sequences are listed in Table S1.

**Mouse lupus.** Using an established model of mouse lupus (Kowal et al., 2004), 6–8-week-old XBP1+/- and XBP1+/- mice were immunized i.p. with 100 µg MAP-DWEYS emulsified in CFA (Sigma-Aldrich). Booster immunizations with 100 µg MAP-DWEYS in IFA (Sigma-Aldrich) were given on days 14 and 28. Serum was obtained from these mice on day 35 and tested for anti-peptide and anti-dsDNA antibodies as previously described (Kowal et al., 2004). There were five mice per group. To disrupt the blood brain barrier in the hippocampus, mice were given i.p. injections of 3 mg/kg LPS (Escherichia coli, 055:B5; Sigma-Aldrich) on days 52 and 54. Mice were then killed 4–7 d after LPS treatment to analyze tissues for histological evidence of mouse SLE. After cardiac perfusion, brains and kidneys were isolated and tissues were immunostained for IgG as previously described (Putterman and Diamond, 1998; Kowal et al., 2004).

**Online supplemental material.** Table S1 lists primer sequences used for quantitative real-time PCR. Fig. S1 shows XBP1 deletion and basal immunoglobulin production in XBP1+/- mice. Fig. S2 shows immunoglobulin production in immunized XBP1+/- mice. Fig. S3 shows in vitro analysis of XBP1-deficient B cells. Fig. S4 shows additional characterization of memory cells in XBP1+/- mice. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20090738/DC1.

We would like to acknowledge Dorothy Zhang and RoseAnn Berlin for their expertise in processing the histological samples, Landy Kangaloo for laboratory assistance, and Marisol Avellaneda for assistance with manuscript submission.

This study was supported by National Institutes of Health grant AI32412 (L.H. Gimcher), The Eliion Foundation (L.H. Gimcher), National Institutes of Health grant T32 AR070530 (D.J. Todd), American College of Rheumatology Fellowship Training Award (D.J. Todd), the American Heart Association Investigator award (A.-H. Lee) and National Institutes of Health grant AI047231 (M.G. McHeyzer-Williams).

The authors have no conflicting financial interests.

Submitted: 2 April 2009
Accepted: 25 August 2009

**REFERENCES**


